Salbutamol and ipratropium by inhaler is superior to nebulizer in children with severe acute asthma exacerbation: Randomized clinical trial
First published: 22 January 2019
Abstract
Introduction
In moderate‐severe asthma exacerbation, salbutamol by inhaler (MDI) is superior to salbutamol delivered by nebulizer (NEB); however, to our knowledge, no studies in children with exclusively severe exacerbations were performed.
Objective
To compare the efficacy of salbutamol and ipratropium bromide by MDI versus by NEB in severe asthma exacerbations.
Methods
We performed a clinical trial enrolling 103 children (2‐14 years of age) with severe asthma exacerbations (defined by the Pulmonary Score ≥ 7) seen at the emergency room in Asuncion, Paraguay. One group received salbutamol and ipratropium (two puff every 10 min for 2 h and then every 30 min for 2 h more) by MDI with a valved‐holding chamber and mask along with oxygen by a cannula separately (MDI‐SIB); and the other received nebulization with oxygen (NEB‐SIB) of salbutamol and ipratropium (1 every 20 min for 2 h and then every 30 min for 2 h more). Primary outcome was the rate of hospitalization (Pulmonary Score ≥ 7) after 4 h and secondary outcome was oxygen saturation.
Results
Fifty two children received MDI‐SIB and 51 NEB‐SIB. After the 4th hour, children on MDI‐SIB had significantly (P = 0.003) lower rate of hospital admission than on NEB‐SIB (5.8% vs 27.5%, RR: 0.21 [0.06‐0.69], respectively). Similarly, a significant improved clinical score after 60 min and increase in oxygen saturation after 90 min of treatment was observed in MDI‐SIB versus NEB‐SIB group (4.46 ± 0.7 vs 5.76 ± 0.65, P < 0.00001; and 90.5 ± 1.7 vs 88.43 1 ± 1, P < 0.00001, respectively).
Conclusion
Even in severe asthma exacerbations administration of salbutamol and ipratropium by MDI with valved‐holding chamber and mask along with oxygen by a cannula separately was more effective than by a nebulizer.
No comments:
Post a Comment